Literature DB >> 31952626

Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Michael D Stein1, Shannon R Kenney2, Bradley J Anderson3, Micah T Conti4, Genie L Bailey5.   

Abstract

BACKGROUND: Persons with opioid use disorder (OUD) are at increased risk for gabapentin misuse. Rising rates of concomitant gabapentin-opioid use in the U.S. are concerning given heightened risk of fatal overdose.
OBJECTIVE: To examine predictors of ever using gabapentin among persons seeking treatment for opioid use and to assess if reasons for gabapentin use differed by gender and how gabapentin was procured (prescribed, non-prescribed, or both).
METHOD: Persons with OUD were recruited from a managed withdrawal program. t-Tests and Pearson χ2 tests of independence were used to compare reasons for gabapentin use by gender and source of acquisition.
RESULTS: Among participants (n = 401; 69.1% male, 84.5% White, 86.8% sought treatment for heroin use, 90.0% insured), female gender, higher educational attainment, injection drug use (IDU), history of overdose, and chronic pain were associated with gabapentin use. Overall, reasons for use were similar across genders among those reporting a history of gabapentin use (65.8%), although males were more likely to use to get high than females. About half (47.0%) reported only using gabapentin that was not prescribed, 20.5% had only used prescribed gabapentin, and 32.5% reported prescribed and non-prescribed use. Persons prescribed gabapentin were most likely to use it to control pain (81.5%); for those using diverted gabapentin only and those reporting both prescribed and non-prescribed gabapentin use, the most common reasons for intake were to: get high, increase effects of heroin, substitute for opioids, and help with opioid withdrawal.
CONCLUSIONS: In this sample of people with OUD entering inpatient detoxification program, a majority reported a history of gabapentin use, with most using diverted gabapentin. The range of reasons for gabapentin use point to the need to better understand why co-use is common.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gabapentin; Harm reduction; Heroin; Opioids; Overdose

Mesh:

Substances:

Year:  2019        PMID: 31952626      PMCID: PMC6981248          DOI: 10.1016/j.jsat.2019.12.007

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  31 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine.

Authors:  Roy R Reeves; Mark E Ladner
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

3.  Prescription medication misuse among opioid dependent patients seeking inpatient detoxification.

Authors:  Timothy Wilens; Courtney Zulauf; Denece Ryland; Nicholas Carrellas; Isela Catalina-Wellington
Journal:  Am J Addict       Date:  2015-03

4.  "That's what we call the cocktail": Non-Opioid medication and supplement misuse among opioid users.

Authors:  Avik Chatterjee; Diego Lopez; Shankar Ramkellawan; Rory Brown; Kamala Smith; Jessie M Gaeta; Travis P Baggett
Journal:  Subst Abus       Date:  2019-10-22       Impact factor: 3.716

5.  Characterization of gabapentin overdose using a poison center case series.

Authors:  Wendy Klein-Schwartz; J Greene Shepherd; Susan Gorman; Brad Dahl
Journal:  J Toxicol Clin Toxicol       Date:  2003

6.  Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population.

Authors:  Alyssa M Peckham; Kirk E Evoy; Jordan R Covvey; Leslie Ochs; Kathleen A Fairman; David A Sclar
Journal:  Pharmacotherapy       Date:  2018-03-28       Impact factor: 4.705

7.  Abuse of Gabapentin is Associated with Opioid Addiction.

Authors:  Leo Bastiaens; James Galus; Cherise Mazur
Journal:  Psychiatr Q       Date:  2016-12

8.  Gabapentin withdrawal presenting as status epilepticus.

Authors:  Fermin Barrueto; Jonah Green; Mary Ann Howland; Robert S Hoffman; Lewis S Nelson
Journal:  J Toxicol Clin Toxicol       Date:  2002

9.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.

Authors:  James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-14       Impact factor: 17.586

10.  Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.

Authors:  Tara Gomes; David N Juurlink; Tony Antoniou; Muhammad M Mamdani; J Michael Paterson; Wim van den Brink
Journal:  PLoS Med       Date:  2017-10-03       Impact factor: 11.069

View more
  5 in total

1.  Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications.

Authors:  Theresa W Kim; Jeffrey H Samet; Sara Lodi; Simeon D Kimmel; Leah S Forman; Marlene C Lira; Jane M Liebschutz; Emily C Williams; Alexander Y Walley
Journal:  AIDS Behav       Date:  2022-06-23

2.  Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market.

Authors:  Sarah E Duhart Clarke; Alex H Kral; Jon E Zibbell
Journal:  Int J Drug Policy       Date:  2021-10-15

3.  A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

Review 4.  Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain.

Authors:  Karin N Westlund; Morgan Zhang
Journal:  Molecules       Date:  2020-03-03       Impact factor: 4.411

5.  Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Psychoactive Drugs       Date:  2020-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.